Sign in

research biologist, medical writer

Mission, Kansas, United States
April 24, 2017

Contact this candidate

Andrei Surguchov,

VA Medical Center,

**** ********** ******, ****** ****, KS 66208



A challenging Medical Writer position, which requires experience reading, understanding, and applying regulations and interpreting data. This position will be based on my experience in writing, understanding and interpreting medical/clinical data and its practical application.


Excellent written and oral communication skills and attention to detail, strong time and project management. Experience and comfort in writing, developing and editing medically-relevant scientific content in the form of manuscripts, abstracts, posters, slides and grant proposals.

Advanced knowledge of scientific, medical and technical writing and editing. Broad experience in biomedical and clinical fields. Knowledge of regulatory guidelines, including FDA, TPD, EMA and others. Expertise in GLP, asnGCP and SOP. Familiarity with current industry practices and regulatory requirements. Ability to interpret and organize highly complex scientific data.

Good interpersonal, verbal and written communication skills.

Understanding and application of principles, concepts, theories and standards of scientific, medical and technical field. Experience in preparation of clinical regulatory document (e.g.,

clinical study reports (CSR), investigators brochures (IB), CTD summary documents, briefing

documents, REMs and REMs assessment reports, IND and other regulatory documents and


Excellent team-working and oral and written communication skills as evidenced by:

oPreparing scientific data for publication: published ~60 review and research papers as a major author.

oPreparing and giving presentations in either oral or poster formats:

30 oral and poster presentations at a variety of scientific meetings.

Writing grant proposals for federal institutions and private foundations. More than 10 of them were funded.

Analytical skills:

Troubleshooting and optimization of experimental procedures.

Analysis of complex scientific results both for laboratory experiments and published data.

Editing and reviewing manuscripts for a peer-reviewed journals.


Working in a goal-oriented collaborative environment.

Leadership/managerial experience:

oInstructed and supervised junior team members.

oEstablished successful relationships with companies technical and sales representatives:


Member of R@D Committee, VA Medical Center, Kansas City.

Committee Member-Reviewer, 7th WSEAS International Conference on Biochemistry and

Medical Chemistry (BIOMEDCH '13), Paris, France, October 2013.

The 2014 International Conference on Biology and Biomedicine (BIO2014), Prague, Czech

Republic, April 2-4, 2014, International Liaisons.

The 2015 International Conference on Biology and Biomedicine (BIO 2015), Barcelona,

Spain, April 7-9, 2015 International Liaisons.

Program Committee: The 2015 International Conference on Biology and Biomedical

Engineering (BBE, Vienna, Austria, March 15-17, 2015).

Committee Member-Reviewer, 6th International Conference on Bioscience and

Bioinformatics (ICBB '15), Dubai, United Arab Emirates, February 22-24, 2015.

Committee Member-Reviewer, 5th International Conference on Biotechnology, Food and Animal

Science, Barcelona - ABIFA '16

Honorable Organizing Committee Member, 2nd World Congress on Biopolymer, Manchester, UK,

August 2016.

Organizing Committee Member at Biopolymers and Bioplastics-2017, 5th International Conference

and Exhibition on Biopolymers and Bioplastics, October 19-21, 2017, San Francisco, USA.


Research biologist and medical writer 2001- 2016 VA Medical Center, Kansas City, MO

Discovered a role of gamma-synuclein as the major contributor to the molecular mechanism of neurodegenerative diseases. Collaborated with 12 scientists on projects studying molecular mechanisms of neurological disorders.

oInvestigated the role of gamma-synuclein as a regulator of gene expression and signaling pathways. Established its role as an initiator of the formation of protein aggregates in brain cells in health and diseases.

oExplored the role of caveolins in retinal diseases, including retinal degeneration and glaucoma.

oInvestigated how matrix metalloproteinases MMP-9 and MMP-2 are implicated in glaucoma, cancer and other diseases.

oPrepared and submitted ~ 15 articles published in high ranking scientific journals.

oPresented 20 oral and poster presentations at the Society for Neuroscience, ARVO and other meetings

oSubmitted several grant proposals, four of which were funded (two in federal institutions and two in private foundations.

Associate Professor 1998 - 2001 Washington University, St. Louis, MO

Performed structure-function studies of synuclein’s role in health and eye diseases. Studied matrix metalloproteinase 9 (MMP-9) in glaucoma and other neurodegenerative diseases.

Published 5 research papers as a major author. Presented 5 oral and poster presentations.

Oversaw the work of a group of 4 junior staff members and technicians in the laboratory of retinal biology.

Submitted several grant proposals, 3 of which were funded.

Senior Investigator 1995-1998 University of Utah, UT

Identified a new retinal protein synoretin (gamma-synuclein) and investigated its role in health and diseases.

Published two research papers and 3 oral/poster presentation at ARVO meetings

Assistant Professor

1992-1995 Baylor College of Medicine, Houston, TX

Investigated genetic control of lipid metabolism and role of apolipoproteins in cardio-vascular diseases

Established a correlation between polymorphism in apolipoprotein III promoter region and predisposition to hyperlipoproteinemia

Found a role of apolipoprotein E (apo-E) in polymorphisms in coding region and the development of atherosclerosis and hyperlipoproteinemia.

Published five articles in scientific journals.


BS, Biochemistry and Molecular Biology, Moscow University, Russia,


Society for Neuroscience, 2010 - current

Association for Research of Vision and Ophthalmology (ARVO) 1995 -2010

Invited reviewer for peer review journals 2006- current


Chapters in the books.

1 International Review of Cell and Molecular Biology, 270, 225-***, ****. A. Surguchov. Molecular

and cellular biology of synucleins.

2 International Review of Cell and Molecular Biology, A. Surguchov. Intracellular dynamics of

synucleins: Here, there and everywhere. 2015, 320:103-169.

3 Surguchov A. in “Protein Aggregation” (Editor: DA. Stein). Folding and unfolding of Synucleins,

Nova Science Publishers, 2011.

4 Surguchov A.” Advances in Brain Research” (Eds: OB. Williams and GI. Wilson). “Two Faced

Members of the Family: The Synucleins”, 2012.

Articles in peer reviewed journals

Pronin AN, Morris AJ, Surguchov A, Benovic JL. Synucleins are a novel class of substrates for G

protein-coupled receptor kinases. J Biol Chem. 2000, 275, 26515-26522 (350 citations).

A. Surguchov, B. McMahon, E. Masliah, I. Surgucheva. Synucleins in ocular tissues. J Neurosci Res,

2001, 65, 68-77.

A. Surguchov, RE. Palazzo, and I. Surgucheva. Gamma synucleins: subcellular localization in

neuronal cells and effect on signal transduction. Cell Motility and Cytoskeleton, 2001, 49, 218-228.

Surgucheva I., McMahan B, F. Ahmed, Tomarev S, Wax MB, Surguchov A. 2002. Synucleins in

glaucoma. J Neurosci Res, 68: 97-106.

Surgucheva I, Sivak, JM, Fini ME, Palazzo RE and Surguchov A. Effect of gamma-synuclein

overexpression on matrix metalloproteinases. Arch Biochem Biophys. 2003, 410:167-176.

Maurage CA, Ruchoux MM, De Vos R, Surguchov A, Destee A. Retinal involvement in dementia with

Lewy bodies: A clue to hallucinations? Ann Neurol. 2003, 54 (4):542-7.

Snyder HM, Mensah K, Surgucheva I, Festoff B, Surguchov A, Wolozin B. g-Synuclein prevents

Proteasomal inhibition by α-synuclein but not γ-synuclein. J Biol Chem, 2005. 4;280:7562-9.

Surgucheva, B. Yue, BC Park, S Tomarev and A. Surguchov. Interaction of myocilin with g-synuclein

and its role in neurodegeneration in glaucoma. Cell Mol Neurobiol, 2005, 25, 6, 1009-33.

Surgucheva I, Ninkina N, Buchman VL, Grasing K, A. Surguchov. Protein aggregation in retinal cells

and approaches to cell protection. Cellular Molecular Neurobiology, 2005, 25, 6, 1051-1066.

Surgucheva I, McMahon B., A. Surguchov. Dynamic intracellular localization of g-synuclein: a clue

to its functions. Cell Motility and Cytoskeleton, 2006, 63, 8, 447-458.

Surgucheva I, Surguchov A. 2008. g-Synuclein: Cell-Type Specific Promoter Activity and Binding to

Transcription Factors. J Mol Neuroscience, 2008; 35(3):267-71.

A. Surguchov. Molecular and cellular biology of synucleins. International Review of Cell and

Molecular Biology, 2008, 270, 225-317.

I Surgucheva, A Shnyra, J Goldberg, A. Weisman and A Surguchov. g-Synuclein as a marker of the

retinal ganglion cells, Molecular Vision, 2008, 14:1540-1548.

I Surgucheva, V Shestopalov and A Surguchov. Effect of g-synuclein silencing on apoptotic

pathways in retinal ganglion cells. J Biol Chem, 2008, 284, (52): 36377-85.

A. Surguchev and A. Surguchov. Conformational Diseases: Looking into the eyes. Brain Research

Bulletin, 2010, 81, 12-24.

Surgucheva I, Chidambaram K, Willoughby DA, Surguchov A. MicroRNA regulates MMP-9

expression. J Ocular Biology, Diseases and Bioinformatics, 2010; 3: 41-52.

Surgucheva I, McMahon B, Surguchov A. Patterns of synuclein expression throughout lens

development. J Biophys Chem. 2010; 1: 12-18.

Surguchov A. in “Protein Aggregation” (Editor: DA. Stein). Folding and unfolding of Synucleins, Nova

Science Publishers, 2011, 7, 179-192.

Surgucheva I and Surguchov A. Expression of caveolins in trabecular meshwork cells and its

implication in pathogenesis of glaucoma. Molecular Vision 2011;17: 2878-2888.

Surgucheva I, Sharov V; Surguchov, A. g-Synuclein: Seeding of α-Synuclein Aggregation and

Transmission Between Cells. Biochemistry, 2012; 51(23):4743-54.

Surguchov A. Synucleins: are they two-edged swords? J Neurosci Res, 2013; 91 (2):161-6.

Surguchov A. Parkinson’s disease: Is there a light at the end of a tunnel? (Editorial). Advances in

Parkinson’s Disease, 2013, 2, 3, 116-117.

Surgucheva I, Gunewardena S, Rao HS, Surguchov A. Cell-specific post-transcriptional regulation of

g-synuclein gene by micro-RNAs. PLOS One, Sep 2013, PONE-D-13-25172.

Surguchov A. What do synucleins do in the nucleus? J Genetics, Mol Cell Biology, 2014, 1, 1.

Surguchov A. SNCG (synuclein, gamma). Atlas Genet Cytogenet Oncol Haematol. June 2014. URL:

Surgucheva I, Newell KL, Burns J and Surguchov A. New alpha- and gamma-Synuclein

Immunopathological Lesions in Human Brain. Acta Neuropathologica Com, 2014, 2: 132.

Surgucheva I, He S, Sharma R, Rich M, Ninkina NN, Stahel P, Surguchov A. Role of synucleins in

traumatic brain injury. Mol Cell Neurosci. 2014, 63, 114–123.

Surguchev A, Surguchov A. Effect of a-synuclein on membrane permeability and synaptic

transmission: a clue to neurodegeneration? J Neurochemistry, 2015; 132 (6): 619-21.

Surguchov A. Intracellular dynamics of synucleins: Here, there and everywhere. International Review

of Cell Molecular Biology, 2015; 320:103-169.

Surguchov A. Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2015, 19, 210-217.

Surguchov A. Parkinson’s disease: early diagnosis and association with melanoma. Brain Sci. 2016,

6(2), 17; doi: 10.3390/brainsci6020017.

Surguchov A. Alterations of secondary structure of naturally unfolded proteins lead to the

accumulation of toxic aggregates. Biopolymers, 2016, submitted.

Surguchov A. Parkinson’s disease: early diagnosis and association with melanoma. Brain Sci. 2016,

6(2), 17; doi: 10.3390/brainsci6020017

Roman A, M Kukharsky, A Surguchov, N Ninkina, V Skvortsova et al., g-Synuclein autoantibody in

the serum of patients with CVD and ALS. Ann Bil Sci, 2016, 470, 5.

Surguchov A. Gamma-Synuclein as a cancer biomarker: viewpoint and new approaches.

Oncomedicine, 2016, 1, 1-3.

Surguchov A. Type-2 diabetes and Parkinson’s disease: a cross-talk between main players. Journal

of Diabetes Mellitus and Metabolic Syndrome, 2016, 1, 1-7.

Surguchov A, Surgucheva I, Sharma M, Singh V. New putative epigenetic mechanism of epilepsy.

Frontiers in Neurology, 2017, 8, 3.



Contact this candidate